Literature DB >> 4077979

Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins.

J S Owen, D J Brown, D S Harry, N McIntyre, G H Beaven, H Isenberg, W B Gratzer.   

Abstract

Echinocytes were frequently found in patients with liver disease when their blood was examined in wet films, but rarely detected in dried, stained smears. When normal erythrocytes (discocytes) were incubated with physiologic concentrations of the abnormal high density lipoproteins (HDL) from some jaundiced patients, echinocytosis developed within seconds. Other plasma fractions were not echinocytogenic. There was a close correlation between the number of echinocytes found in vivo and the ability of the corresponding HDL to induce discocyte-echinocyte transformation. On incubation with normal HDL, echinocytes generated in vitro rapidly reverted to a normal shape, and echinocytes from patients showed a similar trend. Echinocytosis occurred without change in membrane cholesterol content, as did its reversal, and was not caused by membrane uptake of lysolecithin or bile acids. Abnormal, echinocytogenic HDL showed saturable binding to approximately 5,000 sites per normal erythrocyte with an association constant of 10(8) M-1. Nonechinocytogenic patient HDL and normal HDL showed only nonsaturable binding. Several minor components of electrophoretically separated erythrocyte membrane proteins bound the abnormal HDL; pretreatment of the cells with trypsin or pronase reduced or eliminated binding. Echinocytosis by abnormal HDL required receptor occupancy, rather than transfer of constituents to or from the membrane, because cells reversibly prefixed in the discoid shape by wheat germ agglutinin, and then exposed to abnormal HDL, did not become echinocytes when the HDL and lectin were successively removed. Binding did not cause dephosphorylation of spectrin. We conclude that the echinocytes of liver disease are generated from discocytes by abnormal HDL, and we infer that the shape change is mediated by cell-surface receptors for abnormal HDL molecules.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4077979      PMCID: PMC424351          DOI: 10.1172/JCI112237

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  SPUR-CELL ANEMIA: HEMOLYTIC ANEMIA WITH RED CELLS RESEMBLING ACANTHOCYTES IN ALCOHOLIC CIRRHOSIS.

Authors:  J A SMITH; E T LONERGAN; K STERLING
Journal:  N Engl J Med       Date:  1964-08-20       Impact factor: 91.245

2.  Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease.

Authors:  R A Cooper; D B Kimball; J R Durocher
Journal:  N Engl J Med       Date:  1974-06-06       Impact factor: 91.245

3.  Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.

Authors:  G Fairbanks; T L Steck; D F Wallach
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

4.  Editorial: "Acanthocytogenesis"--or how the red cell won its spurs.

Authors:  S E Shohet
Journal:  N Engl J Med       Date:  1974-06-06       Impact factor: 91.245

5.  Present status of spiculed red cells and their relationship to the discocyte-echinocyte transformation: a critical review.

Authors:  G Brecher; M Bessis
Journal:  Blood       Date:  1972-09       Impact factor: 22.113

6.  Role of lipoproteins in the formation of spur cell anaemia.

Authors:  M Martinez-Maldonado
Journal:  J Clin Pathol       Date:  1968-09       Impact factor: 3.411

7.  The acanthocyte in cirrhosis with hemolytic anemia.

Authors:  C C Douglass; M S McCall; E P Frenel
Journal:  Ann Intern Med       Date:  1968-02       Impact factor: 25.391

8.  Spur-shaped erythrocytes in Laennec's cirrhosis.

Authors:  R Silber; E Amorosi; J Lhowe; H J Kayden
Journal:  N Engl J Med       Date:  1966-09-22       Impact factor: 91.245

9.  Anemia with spur cells: a red cell defect acquired in serum and modified in the circulation.

Authors:  R A Cooper
Journal:  J Clin Invest       Date:  1969-10       Impact factor: 14.808

10.  An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease.

Authors:  R A Cooper; M Diloy Puray; P Lando; M S Greenverg
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

View more
  7 in total

1.  New insight into erythrocyte through in vivo surface-enhanced Raman spectroscopy.

Authors:  Nadezda A Brazhe; Salim Abdali; Alexey R Brazhe; Oksana G Luneva; Nadezda Y Bryzgalova; Eugenia Y Parshina; Olga V Sosnovtseva; Georgy V Maksimov
Journal:  Biophys J       Date:  2009-12-16       Impact factor: 4.033

2.  Ultrastructural study of echinocytes induced by poly (ethylene glycol)-cholesterol.

Authors:  Takeshi Baba; Nobuo Terada; Yasuhisa Fujii; Nobuhiko Ohno; Shinichi Ohno; Satoshi B Sato
Journal:  Histochem Cell Biol       Date:  2004-11-18       Impact factor: 4.304

3.  Poikilocytosis in rabbits: prevalence, type, and association with disease.

Authors:  Mary M Christopher; Michelle G Hawkins; Andrew G Burton
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

Review 4.  Adapted Lethality: What We Can Learn from Guinea Pig-Adapted Ebola Virus Infection Model.

Authors:  S V Cheresiz; E A Semenova; A A Chepurnov
Journal:  Adv Virol       Date:  2016-02-18

5.  Is NMDA-Receptor-Mediated Oxidative Stress in Mitochondria of Peripheral Tissues the Essential Factor in the Pathogenesis of Hepatic Encephalopathy?

Authors:  Elena Kosenko; Lyudmila Tikhonova; Gubidat Alilova; Carmina Montoliu
Journal:  J Clin Med       Date:  2022-02-04       Impact factor: 4.241

6.  Elasto-plasticity in wrinkled polymerized lipid membranes.

Authors:  Sahraoui Chaieb
Journal:  Sci Rep       Date:  2014-01-15       Impact factor: 4.379

7.  Single red blood cell analysis reveals elevated hemoglobin in poikilocytes.

Authors:  Suet Man Tsui; Rafay Ahmed; Noreen Amjad; Irfan Ahmed; Jingwei Yang; Francis A Manno; Ishan Barman; Wei-Chuan Shih; Condon Lau
Journal:  J Biomed Opt       Date:  2020-01       Impact factor: 3.170

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.